Physician profile
David Call
NPI 1245233667
$4,776.16
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $861 · 2021: $1,423 · 2022: $1,409 · 2023: $847 · 2024: $55.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $676.18 | 2019-2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $515.40 | 2019-2022 | |
| Abbvie INC. | $360.22 | 2019-2023 | Qulipta, Vraylar |
| Lilly USA, LLC | $342.52 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $249.99 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.78 | 2020-2022 | |
| Pfizer INC. | $209.83 | 2020-2023 | |
| Eisai INC. | $188.49 | 2020-2022 | |
| Amarin Pharma, INC. | $176.32 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.42 | 2022-2023 | |
| Glaxosmithkline, LLC. | $151.03 | 2020-2023 | Trelegy Ellipta |
| Amgen INC. | $131.43 | 2022-2023 | Repatha |
| Astellas Pharma US INC | $114.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $101.91 | 2020-2023 | Farxiga |
| Biogen, INC. | $96.77 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.